ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för nilotinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

29 träffar

Bibliografisk träff 2025-02-04

Association between nilotinib-induced hyperbilirubinemia and UGT1A1 polymorphisms in a chronic myeloid leukemia patient.

Alarcón-Payer C, Sánchez Suárez MDM, Roldán AM, Morales AJ.

Anticancer Drugs · journal article; case reports · DOI 10.1097/cad.0000000000001700

Bibliografisk träff 2025-01-31

A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment.

Alsaati A, Hakami T, Bajawi S, Mohammed G, Bajawi N, Al-Faraidy N.

Dermatol Reports · journal article; case-report · DOI 10.4081/dr.2025.10160

Bibliografisk träff 2024-12-30

Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model.

Sy SKB, Yoon DY, Darstein C, Yang Y, Dasgupta K, Kapoor S, Hoch M, Grosch K.

Br J Clin Pharmacol · clinical trial; journal article · DOI 10.1111/bcp.16381

Bibliografisk träff 2024-11-03

Nilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis.

Sibal S, Patankar A, Raut T.

Cureus · journal article; case reports; case-report · DOI 10.7759/cureus.72952

Bibliografisk träff 2024-09-28

Nilotinib as a Prospective Treatment for Alzheimer's Disease: Effect on Proteins Involved in Neurodegeneration and Neuronal Homeostasis.

Srivastava A, Renna HA, Johnson M, Sheehan K, Ahmed S, Palaia T, Pinkhasov A, Gomolin IH, Wisniewski T, De Leon J, Reiss AB.

Life (Basel) · research-article; journal article · DOI 10.3390/life14101241

Bibliografisk träff 2024-09-01

Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.

Belohlavkova P, Zackova D, Klamova H, Faber E, Karas M, Stejskal L, Cmunt E, Cerna O, Jeziskova I, Machova Polakova K, Zak P, Jurkova T, Chrapava M, Mayer J.

Cancer Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cam4.70158

Bibliografisk träff 2024-07-15

Nilotinib treatment outcomes in autosomal dominant spinocerebellar ataxia over one year.

Lee WJ, Moon J, Jang Y, Shin YW, Son H, Shin S, Jeon D, Han D, Lee ST, Park KI, Jung KH, Lee SK, Chu K.

Sci Rep · clinical trial; research-article; journal article · DOI 10.1038/s41598-024-67072-z

Bibliografisk träff 2022-03-01

A DNA Biosensor Based on a Raspberry-like Hierarchical Nano-structure for the Determination of the Anticancer Drug Nilotinib.

Moarefdoust MM, Jahani S, Moradalizadeh M, Motaghi MM, Foroughi MM.

ChemistryOpen · research-article; journal article · DOI 10.1002/open.202100261

Bibliografisk träff 2016-05-19

High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in Human Plasma from Patients with Chronic Myelogenous Leukemia, and Comparison with Liquid Chromatography-Tandem Mass Spectrometry.

Nakahara R, Satho Y, Itoh H.

J Clin Lab Anal · research-article; journal article · DOI 10.1002/jcla.21975

Bibliografisk träff 2009-08-03

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A.

J Clin Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1200/jco.2009.21.8230

Bibliografisk träff 2009-06-06

The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.

Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2009.06.002

Bibliografisk träff 2009-06-01

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

Breccia M, Alimena G.

Curr Drug Targets · review; journal article · DOI 10.2174/138945009788488468

Bibliografisk träff 2009-05-21

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.

Parise RA, Egorin MJ, Christner SM, Shah DD, Zhou W, Beumer JH.

J Chromatogr B Analyt Technol Biomed Life Sci · research support, non-u.s. gov't; research-article; validation study; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jchromb.2009.05.034

Bibliografisk träff 2009-05-19

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.

Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T.

Int J Hematol · clinical trial, phase ii; clinical trial, phase i; journal article · DOI 10.1007/s12185-009-0327-0

Bibliografisk träff 2009-04-11

Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.

Tiwari AK, Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR, Chen X, Chen ZS.

Biochem Pharmacol · comparative study; journal article · DOI 10.1016/j.bcp.2009.04.002

Bibliografisk träff 2009-02-03

Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.

Sevinc A.

Chemotherapy · journal article; case reports · DOI 10.1159/000198699

Bibliografisk träff 2008-11-01

Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Jarkowski A, Sweeney RP.

Pharmacotherapy · review; journal article · DOI 10.1592/phco.28.11.1374

Bibliografisk träff 2008-10-01

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.

Quintás-Cardama A, Cortes J.

Future Oncol · review; journal article · DOI 10.2217/14796694.4.5.611

Bibliografisk träff 2008-07-01

Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.

Jabbour E, El Ahdab S, Cortes J, Kantarjian H.

Expert Opin Investig Drugs · journal article · DOI 10.1517/13543784.17.7.1127

Bibliografisk träff 2008-03-07

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.

Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jüngel A, Zwerina J, Gay S, Schett G, Distler O, Distler JH.

FASEB J · research support, non-u.s. gov't; journal article · DOI 10.1096/fj.07-105627

Bibliografisk träff 2008-01-08

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.

Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, Maekawa T.

Leuk Res · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.leukres.2007.11.008

Bibliografisk träff 2008-01-01

Nilotinib.

Plosker GL, Robinson DM.

Drugs · review; journal article · DOI 10.2165/00003495-200868040-00005

Bibliografisk träff 2007-10-25

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.

Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N.

Mol Cancer · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/1476-4598-6-67

Bibliografisk träff 2007-10-01

Nilotinib therapy in chronic myelogenous leukemia.

Quintas-Cardama A, Cortes J.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2007.43.10.1122218

Bibliografisk träff 2007-08-24

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2007-07-102061

Bibliografisk träff 2007-07-05

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.

Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG.

Leukemia · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1038/sj.leu.2404827

Bibliografisk träff 2006-11-07

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.

Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2006-08-040022

Bibliografisk träff 2006-10-26

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.

Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, DellaGatta JL, Kung AL, Griffin JD.

Blood · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2006-06-026377

Bibliografisk träff 2006-06-01

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG.

N Engl J Med · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1056/nejmoa055104